✦ LIBER ✦

Ten-year Followup of Infliximab Therapy in Rheumatoid Arthritis Patients with Severe, Longstanding Refractory Disease: A Cohort Study

✍ Scribed by De Keyser, F.; De Kock, J.; Leroi, H.; Durez, P.; Westhovens, R.; Ackerman, C.; Corluy, L.; Debrabanter, G.; Declerck, L.; De Keyser, F.; Dhondt, E.; Durez, P.; Herman, L.; Hermans, P.; Hoffman, I.; Janssens, X.; Kruithof, E.; Lensen, F.; Mielants, H.; Peretz, A.; Poriau, S.; Ravelingien, I.; Stuer, A.; Vandenbruwaene, F.; Vander Cruyssen, B.; Vanhoof, J.; Verbruggen, L.; Volders, P.; Westhovens, R.

Book ID: 124158246
Publisher: Journal of Rheumatology Publishing Company
Year: 2014
Tongue: English
Weight: 380 KB
Volume: 41
Category: Article
ISSN: 0315-162X
DOI: 10.3899/jrheum.131270

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

High ten-year risk of cardiovascular dis

High ten-year risk of cardiovascular disease in newly diagnosed rheumatoid arthritis patients: A population-based cohort study

✍ Hilal Maradit Kremers; Cynthia S. Crowson; Terry M. Therneau; Veronique L. Roger 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 109 KB 👁 2 views

## Abstract ## Objective To estimate the 10‐year absolute risk of cardiovascular (CV) events in newly diagnosed rheumatoid arthritis (RA) patients and the potential contribution of CV risk factors to absolute risk assessment. ## Methods A population‐based incidence cohort of RA patients (defined

Four-year follow-up of infliximab therap

Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity

✍ Vander Bert Cruyssen, Stijn Van Looy, Bart Wyns… 📂 Article 📅 2006 🏛 BioMed Central 🌐 English ⚖ 448 KB

Serum osteopontin level in patients with

Serum osteopontin level in patients with rheumatoid arthritis after one year therapy of infliximab

✍ Kopec-Medrek, M.; Widuchowska, M.; Kotulska, A.; Lis-Swiety, A.; Brzezinska-Wcis 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 44 KB

The efficacy and safety of leflunomide i

The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: A five-year followup study

✍ J. R. Kalden; M. Schattenkirchner; H. Sörensen; P. Emery; C. Deighton; B. Rozman 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 123 KB 👁 2 views

## Abstract ## Objective To investigate the efficacy and safety of leflunomide beyond 2 years in a multinational, open‐label extension of 2 phase III double‐blind studies. ## Methods Patients with rheumatoid arthritis (RA) who received leflunomide (100 mg/day for 3 days, 10 mg/day or 20 mg/day t

Followup radiographic data on patients w

Followup radiographic data on patients with rheumatoid arthritis who participated in a two-year trial of prednisone therapy or placebo

✍ Johannes W. G. Jacobs; Amalia A. Van Everdingen; Suzan M. M. Verstappen; Johanne 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 125 KB 👁 2 views

PAR20 EFFECTS OF LONG-TERM ADALIMUMAB TH

PAR20 EFFECTS OF LONG-TERM ADALIMUMAB THERAPY ON HEALTH UTILITY AND FATIGUE IN PATIENTS WITH LONGSTANDING, SEVERE RHEUMATOID ARTHRITIS (RA)—RESULTS FROM A 3-YEAR FOLLOW-UP STUDY

✍ T Mittendorf; R Sterz; J Von der Schulenburg; H Kupper; M Cifaldi; B Dietz 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 63 KB